vs

Side-by-side financial comparison of Healthpeak Properties (DOC) and Genius Sports Ltd (GENI). Click either name above to swap in a different company.

Healthpeak Properties is the larger business by last-quarter revenue ($702.9M vs $510.9M, roughly 1.4× Genius Sports Ltd). Healthpeak Properties runs the higher net margin — 51.6% vs -12.3%, a 64.0% gap on every dollar of revenue. Over the past eight quarters, Genius Sports Ltd's revenue compounded faster (129.2% CAGR vs 0.5%).

Healthpeak Properties, Inc. is an American real estate investment trust that invests in real estate related to the healthcare industry including senior housing, life science, and medical offices. It was organized in 2007 in Maryland and headquartered in Denver, Colorado with offices in Irvine, Nashville and San Francisco. As of December 31, 2019, the company owned interests in 617 properties.

Genius Sports is a sports data and technology company that provides data management, video streaming and integrity services to sports leagues, bookmakers and media companies.

DOC vs GENI — Head-to-Head

Bigger by revenue
DOC
DOC
1.4× larger
DOC
$702.9M
$510.9M
GENI
Higher net margin
DOC
DOC
64.0% more per $
DOC
51.6%
-12.3%
GENI
Faster 2-yr revenue CAGR
GENI
GENI
Annualised
GENI
129.2%
0.5%
DOC

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
DOC
DOC
GENI
GENI
Revenue
$702.9M
$510.9M
Net Profit
$363.0M
$-63.0M
Gross Margin
25.2%
Operating Margin
0.7%
-11.5%
Net Margin
51.6%
-12.3%
Revenue YoY
-6.6%
Net Profit YoY
28.3%
EPS (diluted)
$0.28

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
DOC
DOC
GENI
GENI
Q1 26
$702.9M
Q4 25
$719.4M
$510.9M
Q3 25
$705.9M
$335.4M
Q2 25
$694.3M
$215.2M
Q1 25
$702.9M
$119.7M
Q4 24
$698.0M
$413.0M
Q3 24
$700.4M
$285.8M
Q2 24
$695.5M
$184.1M
Net Profit
DOC
DOC
GENI
GENI
Q1 26
$363.0M
Q4 25
$114.0M
$-63.0M
Q3 25
$-117.1M
Q2 25
$31.7M
$-47.3M
Q1 25
$42.8M
$-25.5M
Q4 24
$4.5M
$-85.5M
Q3 24
$85.9M
$-47.1M
Q2 24
$146.0M
$-35.5M
Gross Margin
DOC
DOC
GENI
GENI
Q1 26
Q4 25
25.2%
Q3 25
58.6%
24.2%
Q2 25
60.2%
19.1%
Q1 25
61.1%
10.7%
Q4 24
60.3%
16.7%
Q3 24
60.0%
20.5%
Q2 24
60.6%
18.6%
Operating Margin
DOC
DOC
GENI
GENI
Q1 26
0.7%
Q4 25
17.4%
-11.5%
Q3 25
9.2%
-15.3%
Q2 25
5.7%
-21.0%
Q1 25
7.7%
-20.3%
Q4 24
-2.2%
-18.0%
Q3 24
14.1%
-13.9%
Q2 24
22.3%
-16.8%
Net Margin
DOC
DOC
GENI
GENI
Q1 26
51.6%
Q4 25
73.2%
-12.3%
Q3 25
-16.6%
Q2 25
4.6%
-22.0%
Q1 25
6.1%
-21.3%
Q4 24
0.7%
-20.7%
Q3 24
12.3%
-16.5%
Q2 24
21.0%
-19.3%
EPS (diluted)
DOC
DOC
GENI
GENI
Q1 26
$0.28
Q4 25
$0.16
Q3 25
$-0.17
Q2 25
$0.05
Q1 25
$0.06
Q4 24
$0.02
Q3 24
$0.12
Q2 24
$0.21

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
DOC
DOC
GENI
GENI
Cash + ST InvestmentsLiquidity on hand
$-1.2B
$280.6M
Total DebtLower is stronger
Stockholders' EquityBook value
$7.8B
$724.5M
Total Assets
$21.6B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
DOC
DOC
GENI
GENI
Q1 26
$-1.2B
Q4 25
$467.5M
$280.6M
Q3 25
$91.0M
$110.2M
Q2 25
$89.4M
$110.2M
Q1 25
$70.6M
$110.2M
Q4 24
$119.8M
$100.3M
Q3 24
$180.4M
$100.3M
Q2 24
$106.9M
$100.3M
Total Debt
DOC
DOC
GENI
GENI
Q1 26
Q4 25
$9.8B
Q3 25
$9.1B
Q2 25
$9.0B
Q1 25
$8.9B
Q4 24
$8.7B
Q3 24
$8.6B
Q2 24
$8.6B
Stockholders' Equity
DOC
DOC
GENI
GENI
Q1 26
$7.8B
Q4 25
$7.5B
$724.5M
Q3 25
$7.6B
$572.4M
Q2 25
$7.9B
$572.4M
Q1 25
$8.2B
$572.4M
Q4 24
$8.4B
$573.0M
Q3 24
$8.6B
$573.0M
Q2 24
$8.8B
$573.0M
Total Assets
DOC
DOC
GENI
GENI
Q1 26
$21.6B
Q4 25
$20.3B
$1.1B
Q3 25
$19.6B
$792.3M
Q2 25
$19.8B
$792.3M
Q1 25
$19.8B
$792.3M
Q4 24
$19.9B
$775.7M
Q3 24
$20.0B
$775.7M
Q2 24
$20.2B
$775.7M
Debt / Equity
DOC
DOC
GENI
GENI
Q1 26
Q4 25
1.31×
Q3 25
1.20×
Q2 25
1.14×
Q1 25
1.08×
Q4 24
1.04×
Q3 24
1.00×
Q2 24
0.98×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
DOC
DOC
GENI
GENI
Operating Cash FlowLast quarter
$81.9M
Free Cash FlowOCF − Capex
$69.6M
FCF MarginFCF / Revenue
13.6%
Capex IntensityCapex / Revenue
3.4%
2.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$33.5M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
DOC
DOC
GENI
GENI
Q1 26
Q4 25
$1.3B
$81.9M
Q3 25
$315.0M
$-4.8M
Q2 25
$363.5M
$-1.2M
Q1 25
$279.4M
$-14.6M
Q4 24
$1.1B
$14.9M
Q3 24
$318.2M
$-9.2M
Q2 24
$316.2M
Free Cash Flow
DOC
DOC
GENI
GENI
Q1 26
Q4 25
$357.0M
$69.6M
Q3 25
$-14.2M
Q2 25
$-5.8M
Q1 25
$-16.0M
Q4 24
$333.7M
$11.3M
Q3 24
$-11.6M
Q2 24
FCF Margin
DOC
DOC
GENI
GENI
Q1 26
Q4 25
49.6%
13.6%
Q3 25
-4.2%
Q2 25
-2.7%
Q1 25
-13.4%
Q4 24
47.8%
2.7%
Q3 24
-4.1%
Q2 24
Capex Intensity
DOC
DOC
GENI
GENI
Q1 26
3.4%
Q4 25
124.4%
2.4%
Q3 25
2.8%
Q2 25
2.1%
Q1 25
1.2%
Q4 24
105.6%
0.9%
Q3 24
0.9%
Q2 24
Cash Conversion
DOC
DOC
GENI
GENI
Q1 26
Q4 25
10.99×
Q3 25
Q2 25
11.48×
Q1 25
6.52×
Q4 24
235.43×
Q3 24
3.71×
Q2 24
2.17×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

DOC
DOC

Outpatient Medical$320.5M46%
Lab$217.6M31%
Senior Housing$148.9M21%
Other$14.3M2%
Corporate Non-segment$1.5M0%

GENI
GENI

Segment breakdown not available.

Related Comparisons